ArticleTheranostics2018
Multimodal imaging of the receptor for advanced glycation end-products with molecularly targeted nanoparticles.
Article in Theranostics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 36 citations in OpenAlex.
- Deconstruction of Clinical Treatment of Pneumonia and Respiratory Tract Infection Based on MRI Molecular Imaging.Contrast media & molecular imaging · 2022Trial
- Chitosan-Derived Nanocarrier Polymers for Drug Delivery and pH-Controlled Release in Type 2 Diabetes Treatment.Journal of fluorescence · 2025Article
- Review
- Multifunctional nanoparticle for cancer therapy.MedComm · 2023Review
- Molecular Imaging and Nanotechnology-Emerging Tools in Diagnostics and Therapy.International journal of molecular sciences · 2022Review
- Positron Emission Tomography in Animal Models of Alzheimer's Disease Amyloidosis: Translational Implications.Pharmaceuticals (Basel, Switzerland) · 2021Review
- In vivo optical molecular imaging of inflammation and immunity.Journal of molecular medicine (Berlin, Germany) · 2021Review
- Nanoparticle theranostics in cardiovascular inflammation.Seminars in immunology · 2021Review
- Molecularly targeted nanoparticles: an emerging tool for evaluation of expression of the receptor for advanced glycation end products in a murine model of peripheral artery disease.Cellular & molecular biology letters · 2021Article
- Quantitative imaging of the receptor for advanced glycation end-products in prostate cancer.European journal of nuclear medicine and molecular imaging · 2020Article
- Strategies for PET imaging of the receptor for advanced glycation endproducts (RAGE).Journal of pharmaceutical analysis · 2020Article
- Imaging techniques in nanomedical research.European journal of histochemistry : EJH · 2020Article
- Progress of RAGE Molecular Imaging in Alzheimer's Disease.Frontiers in aging neuroscience · 2020Review
- Receptor for Advanced Glycation End Products (RAGE) and Mechanisms and Therapeutic Opportunities in Diabetes and Cardiovascular Disease: Insights From Human Subjects and Animal Models.Frontiers in cardiovascular medicine · 2020Review
- Imaging the Landmarks of Vascular Recovery.Theranostics · 2020Article
- Host-Guest Chemistry in Supramolecular Theranostics.Theranostics · 2019Review
- Targeted nanoparticles for multimodal imaging of the receptor for advanced glycation end-products.Theranostics · 2018Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
The receptor for advanced glycation end-products (RAGE) is central to multiple disease states, including diabetes-related conditions such as peripheral arterial disease (PAD). Despite RAGE's importance in these pathologies, there remains a need for a molecular imaging agent that can accurately assess RAGE levels
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.